ITI-1001 for Glioblastoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new vaccine for brain cancer. It targets patients with newly diagnosed glioblastoma. The vaccine aims to help the immune system fight the cancer. The treatment has been shown to be safe and feasible in previous studies.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, it mentions that patients requiring dexamethasone within 7 days before the first vaccination are excluded, which suggests some medications might need to be stopped. It's best to discuss your specific medications with the trial team.
Are You a Good Fit for This Trial?
Adults over 18 with newly diagnosed glioblastoma who've had most of their tumor surgically removed and are set for standard chemoradiation. They should expect to live at least 3 more months, have good organ function, agree to use contraception, and not be in other clinical trials or have certain health conditions that could interfere with the study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Surgical Resection
Participants undergo gross/near gross total surgical resection of tumor
Vaccination and Chemoradiation
Participants receive 2 priming vaccinations in the 4-6 weeks period between surgery and initiation of SOC chemoradiation, followed by 2 post-chemoradiation priming vaccinations and 5 vaccine boosters with maintenance TMZ
Follow-up
Participants are monitored for safety, efficacy, and immune response, including assessments like NANO scale and peripheral blood T cell activation
What Are the Treatments Tested in This Trial?
Interventions
- ITI-1001
Find a Clinic Near You
Who Is Running the Clinical Trial?
Immunomic Therapeutics, Inc.
Lead Sponsor